- Home
- VOR vs ATTO Comparison
VOR vs ATTO Comparison
Compare VOR & ATTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | ATTO |
|---|---|---|
| Founded | 2015 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | VOR | ATTO |
|---|---|---|
| Price | $19.62 | $15.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $39.00 | ★ $42.20 |
| AVG Volume (30 Days) | ★ 764.3K | 369.4K |
| Earning Date | 11-12-2026 | 09-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.50 | $12.94 |
| 52 Week High | $26.00 | $28.00 |
Technical Indicators
Market Signals| Indicator | VOR | ATTO |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 42.00 |
| Support Level | $17.35 | $12.94 |
| Resistance Level | $20.11 | $24.32 |
| Average True Range (ATR) | 1.16 | 1.37 |
| MACD | 0.29 | 0.31 |
| Stochastic Oscillator | 48.02 | 53.47 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
About ATTO Attovia Therapeutics Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.